IMAGEENS develops software solutions for doctors to leverage advanced medical imaging, commercializing two products: ArtFun+ and LABEL. ArtFun+ calculates vascular stiffness and flow imaging biomarkers that are predictive of long-term risk of death and major cardiovascular events and stems from the NIH-funded MESA study. Its imaging biomarkers have been studied in 77 publications and are used in 31 leading clinical centers. LABEL provides image classification algorithms that enable large medical data warehouses to create metadata and precisely query cohorts for R&D and AI training, and IMAGEENS works with institutions such as AP-HP. The company is pursuing FDA and CE clearance for ArtFun+ to integrate prognostic biomarkers into routine cardiovascular care. IMAGEENS will use the €1.2M seed financing to accelerate development and commercialization of ArtFun+ and LABEL, hire key R&D talent, and scale its commercial team.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2021